Примери за използване на Cerebrovascular events на Английски и техните преводи на Български
{-}
-
Medicine
-
Colloquial
-
Official
-
Ecclesiastic
-
Ecclesiastic
-
Computer
Stroke(cerebrovascular events).
Very rarely reported side effects(may affect up to 1 in 10,000 people): suicide,stroke(cerebrovascular events).
Cardiovascular and Cerebrovascular Events.
The risk of cerebrovascular events associated with ospemifene cannot be excluded.
The patients with untreated hypopituitarism have elevated mortality rates due to cardiovascular and cerebrovascular events.
Cases of stroke(cerebrovascular events) have been reported.
Serious adverse reactions include acute infusion reactions, catheter sepsis, staphylococcal bacteraemia,myocardial infarction, and cerebrovascular events.
The risk of cerebrovascular events is possibly increased with other SERMs.
Over 17 years of follow-up, nearly 3% of HCV seropositive people dieddue to cerebrovascular events, compared with 1% of HCV negative people;
Cerebrovascular events(e.g., transient ischaemic attack, stroke) within the last 3 months.
Nifedipine(Osmo-Adalat) was shown to reduce cardiovascular and cerebrovascular events to a comparable degree as a standard diuretic combination.
Most cerebrovascular events from clinical trials were of migraine, with a higher incidence rate in methylphenidate-treated group compared with placebo group.
Death associated with preeclampsia-eclampsia may be due to cerebrovascular events, renal or hepatic failure, HELLP syndrome, or other complications of hypertension.3.
Following the discussions at the CHMP it was agreed that long-term use data is still needed on a potential effect of methylphenidate on cardiovascular and cerebrovascular events.
Ischaemic or haemorrhagic cerebrovascular events may be contributing or underlying conditions.
No causal association was shown in the three observational studies investigating the risk of seizures,(Rothman, 1990)cardio- and cerebrovascular events,(Herings, 1995) and hypertension(Watson, 1989).
In contrast, three patients(1.5%) had cerebrovascular events in the CHOP group, all of which occurred during the follow-up period.
Caution should be exercised with escalation of Silapo doses in patients with chronic renal failure, since high cumulative epoetin doses may be associated with an increased risk of mortality,serious cardiovascular and cerebrovascular events.
Herings and colleagues concluded that, cardiovascular or cerebrovascular events observed could probably be explained by pre-existing morbidity rather than by the use of bromocriptine.
Caution should be exercised with escalation of Retacrit doses in patients with chronic renal failure since high cumulative epoetin doses may be associated with an increased risk of mortality,serious cardiovascular and cerebrovascular events.
In controlled clinical trials, cerebrovascular events(hemorrhagic and ischaemic strokes) were observed in 3.5% of patients in the Provenge group compared with 2.6% of patients in the control group.
A tendency towards increased risk estimates for all-cause mortality,cardiovascular and cerebrovascular events associated with higher cumulative ESA doses independent of the diabetes or dialysis status was observed(see sections 4.2 and 4.4).
Acute coronary syndrome and cerebrovascular events including arterial dissection and haemorrhagic stroke, pulmonary haemorrhage and transient thrombocytopenia have been identified as risks in close temporal association with the infusion of alemtuzumab.
In clinical trials, an increased risk of death,serious cardiovascular events or cerebrovascular events including stroke were observed when ESAs were administered to target a haemoglobin of greater than 12 g/dl(7.5 mmol/l).
Serious cardiovascular and cerebrovascular events, including myocardial infarction, angina pectoris, cerebrovascular accident and transient ischaemic attack have been uncommonly reported during clinical studies with pemetrexed, usually when given in combination with another cytotoxic agent.
In clinical studies, an increased risk of death,serious cardiovascular or cerebrovascular events including stroke, and vascular access thrombosis was observed when ESAs were administered to target a haemoglobin of greater than 12 g/dl(7.5 mmol/l).
Serious cardiovascular and cerebrovascular events, including myocardial infarction, angina pectoris, cerebrovascular accident and transient ischaemic attack have been uncommonly reported during clinical studies with pemetrexed, usually when given in combination with another cytotoxic agent.
A tendency towards increased risk estimates for all-cause mortality,cardiovascular and cerebrovascular events associated with higher cumulative ESA doses independent of the diabetes or dialysis status was observed(see sections 4.2 and 4.4).
Serious cardiovascular and cerebrovascular events, including myocardial infarction, angina pectoris, cerebrovascular accident and transient ischaemic attack have been uncommonly reported during clinical studies with pemetrexed, usually when given in combination with another cytotoxic agent.
Serious cardiovascular events, including myocardial infarction and cerebrovascular events have been uncommonly reported during clinical studies with pemetrexed, usually when given in combination with another cytotoxic agent.